Literature DB >> 31697849

Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage.

Marek Drozdzik1, Sylwia Szelag-Pieniek1, Mariola Post2, Samir Zeair2, Maciej Wrzesinski2, Mateusz Kurzawski1, Jesus Prieto3, Stefan Oswald4.   

Abstract

Hepatocellular transporter levels were quantified using quantitative reverse transcription polymerase chain reaction and liquid chromatography-tandem mass spectrometry methods. Liver function deterioration (Child-Pugh class C) produced significant protein abundance (mean values) increase (to healthy livers) in P-gp (to 260% (CV (coefficient of variation) 82%)) and MRP4 (CV 230%) (not detected in healthy livers), decrease in MRP2 (to 30% (CV 126%)), NTCP (to 34% (CV 112%)), OCT1 (to 35% (CV 153%)), OATP1B1 (to 46% (CV 73%)), and OATP2B1 (to 27% (CV 230%)), whereas BSEP (CV 99%), MRP3 (CV 106%), OAT2 (CV 97%), OCT3 (CV 113%), and OATP1B3 (CV 144%) remained unchanged. Alcoholic liver disease produced significant protein downregulation of MRP2 (to 30% (CV 134%)), NTCP (to 76% (CV 78%)), OAT2 (to 26% (CV 117%)), OATP1B1 (to 61% (CV 76%)), OATP1B3 (to 79% (CV 160%)), and OATP2B1 (to 73% (CV 90%)) of healthy tissue values. Hepatitis C produced BSEP (to 47% (CV 99%)) and OATP2B1 (to 74% (CV 91%)) protein reduction. Primary biliary cholangitis and primary sclerosing cholangitis demonstrated P-gp and MRP4 protein upregulation (to 350% (CV 47%) and 287% (CV 38%), respectively). Autoimmune hepatitis revealed P-gp (to 410% (CV 49%)) and MRP4 (CV 96%) increase, and MRP2 (to 18% (CV 259%)) protein decrease. Drug transporters' protein abundance depends on liver pathology type and its functional state.
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Year:  2019        PMID: 31697849     DOI: 10.1002/cpt.1717

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.

Authors:  Deepak Ahire; Laken Kruger; Sheena Sharma; Vijaya Saradhi Mettu; Abdul Basit; Bhagwat Prasad
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

2.  Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis.

Authors:  Silvia Di Giacomo; Marco Gullì; Roberta Facchinetti; Marco Minacori; Romina Mancinelli; Ester Percaccio; Caterina Scuderi; Margherita Eufemi; Antonella Di Sotto
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

3.  Hepatic Expression of the Na+-Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation.

Authors:  Roman Tremmel; Anne T Nies; Barbara A C van Eijck; Niklas Handin; Mathias Haag; Stefan Winter; Florian A Büttner; Charlotte Kölz; Franziska Klein; Pascale Mazzola; Ute Hofmann; Kathrin Klein; Per Hoffmann; Markus M Nöthen; Fabienne Z Gaugaz; Per Artursson; Matthias Schwab; Elke Schaeffeler
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

Review 4.  Regulation Mechanisms of Expression and Function of Organic Cation Transporter 1.

Authors:  Giuliano Ciarimboli
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

Review 5.  The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates.

Authors:  Erkka Järvinen; Feng Deng; Wilma Kiander; Alli Sinokki; Heidi Kidron; Noora Sjöstedt
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

6.  Protein Abundance of Drug Transporters in Human Hepatitis C Livers.

Authors:  Marek Droździk; Joanna Lapczuk-Romanska; Christoph Wenzel; Łukasz Skalski; Sylwia Szeląg-Pieniek; Mariola Post; Marta Syczewska; Mateusz Kurzawski; Stefan Oswald
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

Review 7.  Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract.

Authors:  Marek Droździk; Stefan Oswald; Agnieszka Droździk
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

8.  Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.

Authors:  Eman El-Khateeb; Brahim Achour; Zubida M Al-Majdoub; Jill Barber; Amin Rostami-Hodjegan
Journal:  Mol Pharm       Date:  2021-08-24       Impact factor: 4.939

9.  Hepatic drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure.

Authors:  Sylwia Szeląg-Pieniek; Stefan Oswald; Mariola Post; Joanna Łapczuk-Romańska; Marek Droździk; Mateusz Kurzawski
Journal:  Pharmacol Rep       Date:  2021-06-11       Impact factor: 3.024

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.